Cytokines

Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study
Sofia Ramiro, Rémy L M Mostard, César Magro-Checa, Christel M P van Dongen, Tom Dormans, Jacqueline Buijs, Michiel Gronenschild, Martijn D de Kruif, Eric H J van Haren, Tom van Kraaij, Mathie P G Leers, Ralph Peeters, Dennis R Wong, Robert B M Landewé

Annals of the Rheumatic Diseases Jul 2020, annrheumdis-2020-218479; DOI: 10.1136/annrheumdis-2020-218479
Transient monoarthritis and psoriatic skin lesions following COVID-19
Ludovico De Stefano, Silvia Rossi, Carlomaurizio Montecucco, Serena Bugatti

Annals of the Rheumatic Diseases Aug 2020, annrheumdis-2020-218520; DOI: 10.1136/annrheumdis-2020-218520
Targeting IL-6 in COVID-19. Response to: ‘Rational use of tocilizumab in COVID-19’ by Jain and Sharma
Pier Leopoldo Capecchi, Pietro Enea Lazzerini

Annals of the Rheumatic Diseases Jul 2020, annrheumdis-2020-218627; DOI: 10.1136/annrheumdis-2020-218627
Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: ‘More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia’ by Ferraccioli
Emanuel Della-Torre, Corrado Campochiaro, Giulio Cavalli, Giacomo De Luca, Fabio Ciceri, Alberto Zangrillo, Lorenzo Dagna

Annals of the Rheumatic Diseases Jul 2020, annrheumdis-2020-218612; DOI: 10.1136/annrheumdis-2020-218612
More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia
Gianfranco Ferraccioli

Annals of the Rheumatic Diseases Jul 2020, annrheumdis-2020-218523; DOI: 10.1136/annrheumdis-2020-218523
Response to: ‘Rational use of tocilizumab in COVID-19’ by Jain and Sharma
Nicola Potere, Marcello Di Nisio, Donatella Cibelli, Rosa Scurti, Antonella Frattari, Ettore Porreca, Antonio Abbate, Giustino Parruti

Annals of the Rheumatic Diseases Jul 2020, annrheumdis-2020-218626; DOI: 10.1136/annrheumdis-2020-218626
Rational use of tocilizumab in COVID-19
Siddharth Jain, Shefali Khanna Sharma

Annals of the Rheumatic Diseases Jul 2020, annrheumdis-2020-218519; DOI: 10.1136/annrheumdis-2020-218519
Correspondence on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al. Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials – a real-world district general hospital experience
Asim Khan, Alice Cole, Naveen Bhadauria, Munzir El-Hassan, Daud Abdulla, Thomas Axon, Zozik Fattah, Jessica J Manson, Jeronimo Moreno-Cuesta, Dev Mukerjee

Annals of the Rheumatic Diseases Jul 2020, annrheumdis-2020-218528; DOI: 10.1136/annrheumdis-2020-218528
The use of tocilizumab and tofacitinib in patients with resolved hepatitis B infection: a case series
Naomi Serling-Boyd, Amir M Mohareb, Arthur Y Kim, Emily P Hyle, Zachary S Wallace

Annals of the Rheumatic Diseases Jul 2020, annrheumdis-2020-218289; DOI: 10.1136/annrheumdis-2020-218289
TGFβ attenuates cartilage extracellular matrix degradation via enhancing FBXO6-mediated MMP14 ubiquitination
Gangliang Wang, Shuai Chen, Ziang Xie, Shuying Shen, Wenbin Xu, Wenxiang Chen, Xiang Li, Yizheng Wu, Liangping Li, Bin Liu, Xianjun Ding, An Qin, Shunwu Fan

Annals of the Rheumatic Diseases Aug 2020, 79 (8) 1111-1120; DOI: 10.1136/annrheumdis-2019-216911

Main menu

Cytokines

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Cytokines

Pages